310 related articles for article (PubMed ID: 8387187)
1. Pituitary adenylate cyclase activating polypeptide receptors are present on small cell lung cancer cells.
Moody TW; Zia F; Makheja A
Peptides; 1993; 14(2):241-6. PubMed ID: 8387187
[TBL] [Abstract][Full Text] [Related]
2. Pituitary adenylate cyclase activating peptide receptors regulate the growth of non-small cell lung cancer cells.
Zia F; Fagarasan M; Bitar K; Coy DH; Pisegna JR; Wank SA; Moody TW
Cancer Res; 1995 Nov; 55(21):4886-91. PubMed ID: 7585525
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.
Rawlings SR; Piuz I; Schlegel W; Bockaert J; Journot L
Endocrinology; 1995 May; 136(5):2088-98. PubMed ID: 7720658
[TBL] [Abstract][Full Text] [Related]
4. Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.
Zawilska JB; Dejda A; Niewiadomski P; Gozes I; Nowak JZ
J Mol Neurosci; 2005; 25(3):215-24. PubMed ID: 15800375
[TBL] [Abstract][Full Text] [Related]
5. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
[TBL] [Abstract][Full Text] [Related]
6. Interaction of ovine pituitary adenylate cyclase-activating peptide (PACAP-38) with rat lung membranes.
Bitar KG; Coy DH
Peptides; 1993; 14(3):621-7. PubMed ID: 8392724
[TBL] [Abstract][Full Text] [Related]
7. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a common VIP-PACAP receptor in human small intestinal epithelium.
Salomon R; Couvineau A; Rouyer-Fessard C; Voisin T; Lavallée D; Blais A; Darmoul D; Laburthe M
Am J Physiol; 1993 Feb; 264(2 Pt 1):E294-300. PubMed ID: 8383439
[TBL] [Abstract][Full Text] [Related]
9. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
10. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
11. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex.
Zawilska JB; Niewiadomski P; Nowak JZ
Pol J Pharmacol; 2004; 56(2):203-11. PubMed ID: 15156071
[TBL] [Abstract][Full Text] [Related]
12. Presence of highly selective receptors for PACAP (pituitary adenylate cyclase activating peptide) in membranes from the rat pancreatic acinar cell line AR 4-2J.
Buscail L; Gourlet P; Cauvin A; De Neef P; Gossen D; Arimura A; Miyata A; Coy DH; Robberecht P; Christophe J
FEBS Lett; 1990 Mar; 262(1):77-81. PubMed ID: 2156735
[TBL] [Abstract][Full Text] [Related]
13. Characterization of PACAP receptors and signaling pathways in rabbit gastric muscle cells.
Murthy KS; Jin JG; Grider JR; Makhlouf GM
Am J Physiol; 1997 Jun; 272(6 Pt 1):G1391-9. PubMed ID: 9227474
[TBL] [Abstract][Full Text] [Related]
14. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
[TBL] [Abstract][Full Text] [Related]
15. Cyclic lactam analogues of ovine pituitary adenylate cyclase activating polypeptide (PACAP): discovery of potent type II receptor antagonists.
Bitar KG; Somogyvari-Vigh A; Coy DH
Peptides; 1994; 15(3):461-6. PubMed ID: 7937320
[TBL] [Abstract][Full Text] [Related]
16. PACAP and VIP stimulate enzyme secretion in rat pancreatic acini via interaction with VIP/PACAP-2 receptors: additive augmentation of CCK/carbachol-induced enzyme release.
Schmidt WE; Seebeck J; Höcker M; Schwarzhoff R; Schäfer H; Fornefeld H; Morys-Wortmann C; Fölsch UR; Creutzfeldt W
Pancreas; 1993 Jul; 8(4):476-87. PubMed ID: 8103217
[TBL] [Abstract][Full Text] [Related]
17. Characterization of ocular receptors for pituitary adenylate cyclase activating polypeptide (PACAP) and their coupling to adenylate cyclase.
Nilsson SF; De Neef P; Robberecht P; Christophe J
Exp Eye Res; 1994 Apr; 58(4):459-67. PubMed ID: 7925682
[TBL] [Abstract][Full Text] [Related]
18. Regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. II: Effects of the pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide.
Aoki Y; Iwasaki Y; Katahira M; Oiso Y; Saito H
Endocrinology; 1997 May; 138(5):1930-4. PubMed ID: 9112389
[TBL] [Abstract][Full Text] [Related]
19. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
[TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation.
Hashimoto H; Ogawa N; Hagihara N; Yamamoto K; Imanishi K; Nogi H; Nishino A; Fujita T; Matsuda T; Nagata S; Baba A
Mol Pharmacol; 1997 Jul; 52(1):128-35. PubMed ID: 9224822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
